BRKR

Add to Watchlist

Advanced Chart

0.000

0.000(0.000%)

Overview
Forecast
Valuation

Line

Candle

YTD

High

40.210

Open

39.500

VWAP

39.79

Vol

1.78M

Mkt Cap

6.04B

Low

39.230

Amount

70.85M

EV/EBITDA(TTM)

13.94

Total Shares

151.34M

7.95B

EV/OCF(TTM)

31.65

P/S(TTM)

1.76

Bruker Corporation is a developer, manufacturer and distributor of scientific instruments and analytical and diagnostic solutions. The Company’s BSI BioSpin segment designs, manufactures, and distributes enabling life science tools based on magnetic resonance technology. Its BSI CALID segment designs, manufactures and distributes life science mass spectrometry and ion mobility spectrometry solutions, analytical and process analysis instruments and solutions. Its BSI Nano segment designs, manufactures and distributes advanced X-ray instruments, atomic force microscopy instrumentation, advanced fluorescence optical microscopy instruments. Its Bruker Energy & Supercon Technologies (BEST) segment develops and manufactures superconducting and non-superconducting materials and devices for use in renewable energy, energy infrastructure, healthcare and big science research. It offers scanning transmission electron microscopes (STEM). It also offers advanced research Raman microscopy systems.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q1

FY2025Q2

FY2025Q3

772.47M

+7.03%

0.444

-16.25%

818.65M

+2.24%

0.565

+8.67%

882.75M

+2.12%

0.685

+14.21%

Estimates Revision

The market is revising Downward the revenue expectations for Bruker Corporation (BRKR) for FY2025, with the revenue forecasts being adjusted by -2.71% over the past three months. During the same period, the stock price has changed by -30.11%.

Revenue Estimates for FY2025

Revise Downward

-2.71%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-2.75%

In Past 3 Month

Stock Price

Go Down

-30.11%

In Past 3 Month

9 Analyst Rating

53.11% Upside

Wall Street analysts forecast BRKR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BRKR is 61.00 USD with a low forecast of 45.00 USD and a high forecast of 80.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

7 Buy

2 Hold

0 Sell

Strong Buy

53.11% Upside

Current: 39.840

Low

45.00

Averages

61.00

High

80.00

53.11% Upside

Current: 39.840

Low

45.00

Averages

61.00

High

80.00

Wells Fargo

Brandon Couillard

Buy

Maintains

$75 → $60

2025-04-17

Reason

Wells Fargo

Brandon Couillard

Price Target

$75 → $60

2025-04-17

Maintains

Buy

Reason

Barclays

Luke Sergott

Buy

Maintains

$60 → $50

2025-04-10

Reason

Barclays

Luke Sergott

Price Target

$60 → $50

2025-04-10

Maintains

Buy

Reason

Barclays analyst Luke Sergott lowered the firm's price target on Bruker to $50 from $60 and keeps an Overweight rating on the shares as part of a Q1 earnings preview for life science tools and diagnostics group. Tools are still defensive, but less so than in the past given the threat of the pharma-specific tariffs potentially causing another round of budget cuts, the analyst tells investors in a research note. Barclays also downgraded the contract research organizations on lower visibility.

Citigroup

Patrick Donnelly

Strong Buy

Maintains

$75 → $50

2025-04-07

Reason

Citigroup

Patrick Donnelly

Price Target

$75 → $50

2025-04-07

Maintains

Strong Buy

Reason

Citi lowered the firm's price target on Bruker to $50 from $75 and keeps a Buy rating on the shares as part of a Q1 preview for the life science tools and diagnostics group. The firm believes tariffs and the National Institutes of Health spending cuts are overhands on the sector.

Guggenheim

Subbu Nambi

Strong Buy

Reiterates

n/a

2025-02-24

Reason

Guggenheim

Subbu Nambi

Price Target

n/a

2025-02-24

Reiterates

Strong Buy

Reason

Stifel

Daniel Arias

Hold

Maintains

$70 → $57

2025-02-14

Reason

Stifel

Daniel Arias

Price Target

$70 → $57

2025-02-14

Maintains

Hold

Reason

Barclays

Luke Sergott

Buy

Maintains

$65 → $60

2025-02-14

Reason

Barclays

Luke Sergott

Price Target

$65 → $60

2025-02-14

Maintains

Buy

Reason

Barclays analyst Luke Sergott lowered the firm's price target on Bruker to $65 from $69 and keeps an Overweight rating on the shares. The firm expects the life science tools and diagnostics group to be down today and sentiment to shift more negative following Friday's news around the Trump Administration's implementation of a 15% cap for National Institutes of Health reimbursement of "indirect costs" on the grants it awards universities. The news likely elevates concern on names like Bruker (BRKR), genomics Illumina (ILMN), 10x Genomics (TXG), and PacBio (PACB) and Thermo Fisher (TMO), Avantor (AVTR), Agilent (A), and Waters (WAT) to a lesser extent, the analyst tells investors in a research note.

See All Ratings

Valuation Metrics

The current forward P/E ratio for Bruker Corp (BRKR.O) is 15.17, compared to its 5-year average forward P/E of 28.18. For a more detailed relative valuation and DCF analysis to assess Bruker Corp 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

Strongly Undervalued

5Y Average PE

28.18

Current PE

15.17

Overvalued PE

33.87

Undervalued PE

22.48

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

Strongly Undervalued

5Y Average EV/EBITDA

18.32

Current EV/EBITDA

12.00

Overvalued EV/EBITDA

21.19

Undervalued EV/EBITDA

15.46

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Strongly Undervalued

5Y Average PS

3.50

Current PS

1.73

Overvalued PS

4.29

Undervalued PS

2.72

Financials

Annual

Quarterly

FY2024Q4

YoY :

+14.64%

979.60M

Total Revenue

FY2024Q4

YoY :

+11.71%

153.60M

Operating Profit

FY2024Q4

YoY :

-92.44%

15.40M

Net Income after Tax

FY2024Q4

YoY :

-93.57%

0.09

EPS - Diluted

FY2024Q4

YoY :

-11.90%

153.30M

Free Cash Flow

FY2024Q4

YoY :

-0.12%

50.54

Gross Profit Margin - %

FY2024Q4

YoY :

-50.73%

4.04

FCF Margin - %

FY2024Q4

YoY :

-94.07%

1.42

Net Margin - %

FY2024Q4

YoY :

-75.75%

4.23

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

193.7K

USD

6-9

Months

295.8K

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds areBuying! The buying amount has increased 1214.94% over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

1.0M

Volume

6-9

Months

0.0

Volume

0-12

Months

180.0K

Volume

Bought

0-3

0.0

Volume

Months

3-6

3.5M

Volume

Months

6-9

0.0

Volume

Months

0-12

262.0K

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

193.7K

USD

6-9

Months

295.8K

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

BRKR News & Events

Events Timeline

2025-04-16 (ET)

2025-04-16

06:01:51

Bruker annouces majority investment in RECIPE Chemicals + Instruments

2025-04-11 (ET)

2025-04-11

08:06:49

Bruker reports preliminary Q1 revenue $795M-$800M, consensus $757.03M

2025-04-07 (ET)

2025-04-07

07:02:01

Bruker announces launch of Fourier 80 FT-NMR spectrometer

News

3.5

04-25Newsfilter

Bruker Spatial Biology Pushes Boundaries in Spatial Biology and Multiomics at AACR 2025

5.0

04-24Newsfilter

Bruker to Launch Beacon Discovery™ at AACR 2025, Expanding Access to Live Single-Cell Functional Analysis

5.0

04-23Newsfilter

Solis Agrosciences Names Crystal Winkeler Chief Business Officer to Drive Commercial Growth

People Also Watch

Alerus Financial Corp

Flushing Financial Corp

Southern California Bancorp

Rayonier Advanced Materials Inc

Senseonics Holdings Inc

Peoples Financial Services Corp

FAQ

What is Bruker Corp (BRKR) stock price today?

The current price of BRKR is 39.84 USD — it has increased 0.45 % in the last trading day.

BRKR

Market Estimates

Valuation Metrics

Forward PE

Forward EV/EBITDA

Forward PS

Financials

Trading Trends

BRKR News & Events

Events Timeline

News

People Also Watch

FAQ

What is Bruker Corp (BRKR) stock price today?

What is Bruker Corp (BRKR)'s business?

What is the price predicton of BRKR Stock?

What is Bruker Corp (BRKR)'s revenue for the last quarter?

What is Bruker Corp (BRKR)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Bruker Corp (BRKR)'s fundamentals?

How many employees does Bruker Corp (BRKR). have?

What is Bruker Corp (BRKR) market cap?